Clinical trials: Sirolimus, completed
Uveal Melanoma
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
The purpose of this study is to find out what effects, good and/or bad, the drugs everolimus and pasireotide have on the patient and on melanoma. Pasireotide is also called SOM-230.
- Trial name
- NCT01252251
- Testing
- RAD001 (Everolimus) and Pasireotide (SOM230) LAR
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Immunosuppression, Kidney Transplantation
HLA-Identical Sibling Renal Transplant Tolerance
The purpose of this study is to attempt to eliminate the necessity of immunosuppressive therapy for HLA-identical sibling Kidney Transplants, examine cellular chimerism of donor hematopoietic stem cell (DHSC) lineages for pairs…
- Conditions
- Immunosuppression, Kidney Transplantation, Graft Rejection
- Trial name
- NCT00619528
- Testing
- Infusion of Donor Hematopoietic Stem Cells and Campath-1H
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Conventional Chondrosarcoma, Myxoid Liposarcoma
Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease…
- Conditions
- Conventional Chondrosarcoma, Myxoid Liposarcoma, Mesenchymal Chondrosarcoma, Dedifferentiated Chondrosarcoma
- Trial name
- NCT02821507
- Testing
- sirolimus and cyclophosphamide
- Where
- 7 sites in Netherlands, Spain
- Volunteers
- 70 people
- Sponsor
- Leiden University Medical Center
Transplantation Infection, Cytomegalovirus Infection
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after transplantation. It is associated with an increased incidence of acute rejection and lower graft and patient survivals.
- Trial name
- EVERCMV (NCT02328963)
- Testing
- Everolimus, mycophenolic acid
- Where
- 9 sites in France
- Volunteers
- 186 people
- Sponsor
- University Hospital, Bordeaux
Coronary Arteriosclerosis
Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions
To evaluate the safety, efficacy and deliverability of the Combo bio-engineered sirolimus-eluting stent versus the Nano polymer-free sirolimus- eluting stents in the treatment of patients with de novo stenotic lesions of native…
- Trial name
- RECOVERY (NCT02542007)
- Testing
- OrbusNeich Combo stent™, sirolimus-eluting stent system
- Where
- 15 sites in China
- Volunteers
- 440 people
- Sponsor
- OrbusNeich
Planned Kidney Transplantation
Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation
Calcineurin inhibitors, such as cyclosporine and tacrolimus, have improved allograft survival in kidney organ transplantation. Indeed, they have reduced the incidence of acute rejection episodes of cadaveric allograft recipients.
- Trial name
- NCT01706471
- Testing
- Everolimus + Low dose CsA +PD, Myfortic+ Standard CsA + PD
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Renal Transplantation
Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation
To investigate in renal transplant recipients the potential drug intreaction between Sirolimus, Mycophenolt Mofetil and Fluvastatin All patient enrolled in this PKI-Study had no changes in the therapy before or because of the…
- Trial name
- NCT00223028
- Testing
- sirolimus, mycophenolat mofetil, fluvastatin
- Volunteers
- 15 people
- Sponsor
- University Hospital Schleswig-Holstein
Renal Transplant
Pilot Study for HLA Identical Living Donor Renal Transplant Recipients
The purpose of this study is to evaluate the safety and effectiveness of a steroid-free and calcineurin-inhibitor free treatment regimen for patients who are receiving a kidney transplant from a living donor that is HLA-identical…
- Trial name
- NCT00352092
- Testing
- calcineurin inhibitor, sirolimus, mycophenolate mofetil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Hepatocellular Carcinoma
RAD001 in Advanced Hepatocellular Carcinoma
Laboratory studies have shown that RAD001 can prevent cells from multiplying. Consequently, the study drug is being tested in medical conditions in which excessive cell multiplication (as in cancer) needs to be stopped.
- Trial name
- NCT00516165
- Testing
- RAD001
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus
Reparixin in Pancreatic Islet Transplantation
Inhibition of CXCL8 activity might represent a relevant therapeutic target to prevent injury occurring after pancreatic islet transplantation. Reparixin is a novel and specific inhibitor of CXCL8.
- Trial name
- NCT01220856
- Testing
- Reparixin
- Where
- 2 sites in Germany, Italy
- Volunteers
- 9 people
- Sponsor
- Dompé Farmaceutici S.p.A
Cardiac Transplantation
Everolimus in de Novo Heart Transplant Recipients
The purpose of this study, in de novo heart transplant patients, is to evaluate whether delayed introduction of everolimus reduces the occurrence of wound healing problems, pericardial and/or pleural effusion and early acute…
- Trial name
- EVERHEART (NCT01017029)
- Testing
- Everolimus, Mycophenolate mofetil + Everolimus
- Where
- 12 sites in Italy
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Renal Transplantation
Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients
Cyclosporine (CNI), a potent immunosuppressive drug used in transplant recipients to prevent graft rejection, can cause renal impairment in some patients.
- Trial name
- NCT00443937
- Testing
- enteric-coated mycophenolate sodium, everolimus
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Charite University, Berlin, Germany
Colorectal Cancer
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
RAD001 (everolimus) is a novel oral derivative of rapamycin. RAD001 has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation and has obtained marketing authorization (Certican®) for…
- Trial name
- NCT01047293
- Testing
- RAD001, FOLFOX, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of Utah
Coronary Artery Disease, Coronary Atherosclerosis
Everolimus Stent in Patients With Coronary Artery Disease (CAD)
Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers PCI eligible patients
- Trial name
- RACES (NCT01182649)
- Testing
- coronary stent, stent
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- San Giuseppe Moscati Hospital
Age-Related Macular Degeneration
Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD
This study will determine if a drug called sirolimus is safe to give to people with geographic atrophy GA and if it can help preserve vision in patients. GA is an advanced form of dry age-related macular degeneration (AMD).
- Trial name
- SIRGA (NCT00766649)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Eye Institute (NEI)
Graft-versus-host Disease, Survival
Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation
To evaluate if rapamune + tacrolimus immunosuppressive prophylaxis is better than the established therapy using cyclosporine and methotrexate, a Nordic prospective multicenter randomized study will be performed.
- Trial name
- NCT00993343
- Testing
- Sirolimus/tacrolimus, cyclosporine/methotrexate
- Where
- Sweden
- Volunteers
- 215 people
- Sponsor
- Karolinska Institutet
BK Virus Infection
Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
This study is examining the safety and efficacy of converting anti-rejection therapy from mycophenolic acid (MPA) to Zortress (everolimus) in renal transplant recipients with BK virus infection.
- Trial name
- NCT01624948
- Testing
- Everolimus, Mycophenolic acid dose reduction
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Non Small Cell Lung Cancer
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.
- Trial name
- NCT00456833
- Testing
- RAD001, erlotinib
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
Targeting molecular pathways of tumor growth has become a major focus of anti-cancer treatments. This study aims to investigate the toxicity, pharmacokinetics, and preliminary efficacy of the triplet combination of bevacizumab…
- Trial name
- BEP (NCT00586443)
- Testing
- bevacizumab, everolimus, panitumumab
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Herbert Hurwitz, MD
Coronary Stenosis
The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R.)
1500 eligible patients will be treated with the commercially available CYPHER® sirolimus-eluting Bx Velocity™ stent. Patients will be followed to twelve months post-procedure, watching for patients that require a repeat procedure…
- Trial name
- NCT00403338
- Testing
- CYPHER® Bx Velocity™ stent (sirolimus-eluting)
- Volunteers
- 1,500 people
- Sponsor
- Cordis US Corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.